Skip to content
2000
  1. Home
  2. A-Z Publications
  3. The International Journal of Gastroenterology and Hepatology Diseases
  4. Volume 3, Issue 1
  5. Article
Volume 3, Issue 1
  • ISSN: 2666-2906
  • E-ISSN: 2666-2914

Abstract

Hepatic encephalopathy is a neurological condition that affects people who have an insufficient liver function. However, its pathophysiology is yet unclear. For hepatic encephalopathy, pharmacotherapy is the primary treatment choice. Lowering ammonia levels, enhancing neurotransmitter signal transduction, and modifying gut microbiota, tackles the pathophysiology of hepatic encephalopathy. The intestinal microbiota of liver disease patients differs greatly from that of healthy people, and this difference is linked to the development of hepatic encephalopathy. Additionally, gut microbiota is intimately linked to several theories in the pathophysiology of hepatic encephalopathy, such as the GABA-ergic tone hypothesis, bile acid circulation, ammonia poisoning theory, and neuroinflammation, all of which exacerbate patients' cognitive and motor impairments. Providing some probiotics or reestablishing the intestinal bacteria's balance has a substantial impact on neurological illnesses in hepatic encephalopathy. The goal of this review is to determine the possible metabolic impacts and microbiological pathways in the gut-brain axis mediated progression of hepatic encephalopathy, as well as its potential function as a therapeutic target.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ijghd/10.2174/0126662906301568240427100342
2024-05-06
2025-01-19

  • From This Site

    /content/journals/ijghd/10.2174/0126662906301568240427100342
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MichalskaC.I. SzczepanekM. SłowikA. MachT. Pathogenesis of hepatic encephalopathy.Gastroenterol. Res. Pract.201220121710.1155/2012/642108 23316223
     [Google Scholar]
  2. HadjihambiA. AriasN. SheikhM. JalanR. Hepatic encephalopathy: A critical current review.Hepatol. Int.201812S113514710.1007/s12072‑017‑9812‑3 28770516
     [Google Scholar]
  3. ChenZ. RuanJ. LiD. WangM. HanZ. QiuW. WuG. The role of intestinal bacteria and gut–brain axis in hepatic encephalopathy.Front. Cell. Infect. Microbiol.20211059575910.3389/fcimb.2020.595759 33553004
     [Google Scholar]
  4. FrederickR.T. Current concepts in the pathophysiology and management of hepatic encephalopathy.Gastroenterol. Hepatol.201174222233 21857820
     [Google Scholar]
  5. JaffeA. LimJ.K. JakabS.S. Pathophysiology of hepatic encephalopathy.Clin. Liver Dis.202024217518810.1016/j.cld.2020.01.002 32245525
     [Google Scholar]
  6. AlsahharJ.S. RahimiR.S. Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.Curr. Opin. Gastroenterol.201935314515410.1097/MOG.0000000000000527 30893082
     [Google Scholar]
  7. AldridgeD.R. TranahE.J. ShawcrossD.L. Pathogenesis of hepatic encephalopathy: Role of ammonia and systemic inflammation.J. Clin. Exp. Hepatol.20155S1S7S2010.1016/j.jceh.2014.06.004 26041962
     [Google Scholar]
  8. FerenciP. Hepatic encephalopathy.Gastroenterol. Rep.20175213814710.1093/gastro/gox013 28533911
     [Google Scholar]
  9. CarabottiM. SciroccoA. MaselliM.A. SeveriC. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems.Ann. Gastroenterol.2015282203209 25830558
     [Google Scholar]
  10. ClappM. AuroraN. HerreraL. BhatiaM. WilenE. WakefieldS. Gut microbiota’s effect on mental health: The gut-brain axis.Clin. Pract.20177498710.4081/cp.2017.987 29071061
     [Google Scholar]
  11. DashS. SyedY.A. KhanM.R. Understanding the role of the gut microbiome in brain development and its association with neurodevelopmental psychiatric disorders.Front. Cell Dev. Biol.20221088054410.3389/fcell.2022.880544 35493075
     [Google Scholar]
  12. RoccoA. SgamatoC. CompareD. CoccoliP. NardoneO.M. NardoneG. gut microbes and hepatic encephalopathy: from the old concepts to new perspectives.Front. Cell Dev. Biol.2021974825310.3389/fcell.2021.748253 34900994
     [Google Scholar]
  13. FurnessJ.B. CallaghanB.P. RiveraL.R. ChoH.J. The enteric nervous system and gastrointestinal innervation: Integrated local and central control.Adv. Exp. Med. Biol.2014817397110.1007/978‑1‑4939‑0897‑4_3 24997029
     [Google Scholar]
  14. HuB. AryaA.K. Brain–gut axis after stroke.Brain Circ.20184416517310.4103/bc.bc_32_18 30693343
     [Google Scholar]
  15. LiangJ. LiuB. DongX. WangY. CaiW. ZhangN. ZhangH. Decoding the role of gut microbiota in Alzheimer’s pathogenesis and envisioning future therapeutic avenues.Front. Neurosci.202317124225410.3389/fnins.2023.1242254 37790586
     [Google Scholar]
  16. MittalR. DebsL.H. PatelA.P. NguyenD. PatelK. O’ConnorG. GratiM. MittalJ. YanD. EshraghiA.A. DeoS.K. DaunertS. LiuX.Z. Neurotransmitters: The critical modulators regulating gut–brain axis.J. Cell. Physiol.201723292359237210.1002/jcp.25518 27512962
     [Google Scholar]
  17. ChenM. RuanG. ChenL. YingS. LiG. XuF. XiaoZ. TianY. LvL. PingY. ChengY. WeiY. Neurotransmitter and intestinal interactions: focus on the microbiota-gut-brain axis in irritable bowel syndrome.Front. Endocrinol.20221381710010.3389/fendo.2022.817100 35250873
     [Google Scholar]
  18. SyromyatnikovM. NesterovaE. GladkikhM. SmirnovaY. GryaznovaM. PopovV. Characteristics of the gut bacterial composition in people of different nationalities and religions.Microorganisms2022109186610.3390/microorganisms10091866 36144468
     [Google Scholar]
  19. RinninellaE. RaoulP. CintoniM. FranceschiF. MiggianoG. GasbarriniA. MeleM. What is the healthy gut microbiota composition? a changing ecosystem across age, environment, diet, and diseases.Microorganisms2019711410.3390/microorganisms7010014 30634578
     [Google Scholar]
  20. JiangW. WuN. WangX. ChiY. ZhangY. QiuX. HuY. LiJ. LiuY. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease.Sci. Rep.201551809610.1038/srep08096 25644696
     [Google Scholar]
  21. LlorenteC. SchnablB. The gut microbiota and liver disease.Cell. Mol. Gastroenterol. Hepatol.20151327528410.1016/j.jcmgh.2015.04.003 26090511
     [Google Scholar]
  22. JasirwanC.O.M. LesmanaC.R.A. HasanI. SulaimanA.S. GaniR.A. The role of gut microbiota in non-alcoholic fatty liver disease: Pathways of mechanisms.Biosci. Microbiota Food Health2019383818810.12938/bmfh.18‑032 31384519
     [Google Scholar]
  23. ZhuL. XiaoM. LuoJ. LiS. LiuW. WuJ. SongZ. Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE−/− mice.Int. J. Biol. Macromol.202323512385310.1016/j.ijbiomac.2023.123853 36863676
     [Google Scholar]
  24. ZhangX.L. ChenL. YangJ. ZhaoS.S. JinS. AoN. YangJ. LiuH.X. DuJ. Vitamin D alleviates non-alcoholic fatty liver disease via restoring gut microbiota and metabolism.Front. Microbiol.202314111764410.3389/fmicb.2023.1117644 36819064
     [Google Scholar]
  25. MaestriM. SantopaoloF. PompiliM. GasbarriniA. PonzianiF.R. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies.Front. Nutr.202310111053610.3389/fnut.2023.1110536 36875849
     [Google Scholar]
  26. LinD. SunQ. LiuZ. PanJ. ZhuJ. WangS. JiaS. ZhengM. LiX. GongF. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.Free Radic. Biol. Med.202319519921810.1016/j.freeradbiomed.2022.12.087 36586452
     [Google Scholar]
  27. HuangX. ChenQ. FanY. YangR. GongG. YanC. SongY. ZhangB. XiS. HuangY. XuH. Fructooligosaccharides attenuate non-alcoholic fatty liver disease by remodeling gut microbiota and association with lipid metabolism.Biomed. Pharmacother.202315911430010.1016/j.biopha.2023.114300 36696803
     [Google Scholar]
  28. TangY. ChenB. HuangX. HeX. YiJ. ZhaoH. TianF. LiuY. LiuB. Fu brick tea alleviates high fat induced non-alcoholic fatty liver disease by remodeling the gut microbiota and liver metabolism.Front. Nutr.20229106232310.3389/fnut.2022.1062323 36618677
     [Google Scholar]
  29. CaoF. DingQ. ZhugeH. LaiS. ChangK. LeC. YangG. ValencakT.G. LiS. RenD. Lactobacillus plantarum ZJUIDS14 alleviates non-alcoholic fatty liver disease in mice in association with modulation in the gut microbiota.Front. Nutr.20239107128410.3389/fnut.2022.1071284 36698477
     [Google Scholar]
  30. DahlS. KircheisG. HäussingerD. Hepatic encephalopathy as a complication of liver disease.World J. Gastroenterol.20017215215610.3748/wjg.v7.i2.152 11819754
     [Google Scholar]
  31. DhimanR.K. Gut microbiota and hepatic encephalopathy.Metab. Brain Dis.201328232132610.1007/s11011‑013‑9388‑0 23463489
     [Google Scholar]
  32. ShahbaziA. SepehrinezhadA. VahdaniE. JamaliR. GhasempourM. MassoudianS. NegahS.S. LarsenF.S. Gut Dysbiosis and Blood-Brain Barrier Alteration in Hepatic Encephalopathy: From Gut to Brain.Biomedicines2023115127210.3390/biomedicines11051272 37238943
     [Google Scholar]
  33. TangW. ZhuH. FengY. GuoR. WanD. The Impact of Gut Microbiota Disorders on the Blood–Brain Barrier.Infect. Drug Resist.2020133351336310.2147/IDR.S254403 33061482
     [Google Scholar]
  34. De LucaF. ShoenfeldY. The microbiome in autoimmune diseases.Clin. Exp. Immunol.20181951748510.1111/cei.13158 29920643
     [Google Scholar]
  35. GasalyN. de VosP. HermosoM.A. Impact of bacterial metabolites on gut barrier function and host immunity: a focus on bacterial metabolism and its relevance for intestinal inflammation.Front. Immunol.20211265835410.3389/fimmu.2021.658354 34122415
     [Google Scholar]
  36. SittipoP. ChoiJ. LeeS. LeeY.K. The function of gut microbiota in immune-related neurological disorders: A review.J. Neuroinflammation202219115410.1186/s12974‑022‑02510‑1 35706008
     [Google Scholar]
  37. BiesmansS. MeertT.F. BouwknechtJ.A. ActonP.D. DavoodiN. De HaesP. KuijlaarsJ. LangloisX. MatthewsL.J.R. Ver DonckL. HellingsN. NuydensR. Systemic immune activation leads to neuroinflammation and sickness behavior in mice.Mediators Inflamm.2013201311410.1155/2013/271359 23935246
     [Google Scholar]
  38. AzhariH. SwainM.G. Role of Peripheral Inflammation in Hepatic Encephalopathy.J. Clin. Exp. Hepatol.20188328128510.1016/j.jceh.2018.06.008 30302045
     [Google Scholar]
  39. DhimanR.K. Gut microbiota, inflammation and hepatic encephalopathy: A puzzle with a solution in sight.J. Clin. Exp. Hepatol.20122320721010.1016/j.jceh.2012.08.004 25755435
     [Google Scholar]
  40. BajajJ.S. HylemonP.B. RidlonJ.M. HeumanD.M. DaitaK. WhiteM.B. MonteithP. NobleN.A. SikaroodiM. GillevetP.M. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.Am. J. Physiol. Gastrointest. Liver Physiol.20123036G675G68510.1152/ajpgi.00152.2012 22821944
     [Google Scholar]
  41. LapidesD.A. McDonaldM.M. Inflammatory manifestations of systemic diseases in the central nervous system.Curr. Treat. Options Neurol.20202292610.1007/s11940‑020‑00636‑2 32834714
     [Google Scholar]
  42. SilvaY.P. BernardiA. FrozzaR.L. The Role of short-chain fatty acids from gut microbiota in gut-brain communication.Front. Endocrinol.2020112510.3389/fendo.2020.00025 32082260
     [Google Scholar]
  43. van de WouwM. BoehmeM. LyteJ.M. WileyN. StrainC. O’SullivanO. ClarkeG. StantonC. DinanT.G. CryanJ.F. Short‐chain fatty acids: Microbial metabolites that alleviate stress‐induced brain–gut axis alterations.J. Physiol.2018596204923494410.1113/JP276431 30066368
     [Google Scholar]
  44. WuG. JiangZ. PuY. ChenS. WangT. WangY. XuX. WangS. JinM. YaoY. LiuY. KeS. LiuS. Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients.BMC Neurol.20222211310.1186/s12883‑021‑02544‑7 34996385
     [Google Scholar]
  45. HuangP. ZhangP. DuJ. GaoC. LiuJ. TanY. ChenS. Association of fecal short-chain fatty acids with clinical severity and gut microbiota in essential tremor and its difference from Parkinson’s disease.NPJ Parkinsons Dis.20239111510.1038/s41531‑023‑00554‑5 37460569
     [Google Scholar]
  46. YangX. AiP. HeX. MoC. ZhangY. XuS. LaiY. QianY. XiaoQ. Parkinson’s disease is associated with impaired gut–blood barrier for short‐chain fatty acids.Mov. Disord.20223781634164310.1002/mds.29063 35607987
     [Google Scholar]
  47. DasarathyS. MookerjeeR.P. RackayovaV. ThraneR.V. VairappanB. OttP. RoseC.F. Ammonia toxicity: From head to toe?Metab. Brain Dis.201732252953810.1007/s11011‑016‑9938‑3 28012068
     [Google Scholar]
  48. JinY. SinghP. ChungH.J. HongS.T. blood ammonia as a possible etiological agent for alzheimer’s disease.Nutrients201810556410.3390/nu10050564 29734664
     [Google Scholar]
  49. AverinaO.V. ZorkinaY.A. YunesR.A. KovtunA.S. UshakovaV.M. MorozovaA.Y. KostyukG.P. DanilenkoV.N. ChekhoninV.P. bacterial metabolites of human gut microbiota correlating with depression.Int. J. Mol. Sci.20202123923410.3390/ijms21239234 33287416
     [Google Scholar]
  50. WonS.M. OhK.K. GuptaH. GanesanR. SharmaS.P. JeongJ.J. YoonS.J. JeongM.K. MinB.H. HyunJ.Y. ParkH.J. EomJ.A. LeeS.B. ChaM.G. KwonG.H. ChoiM.R. KimD.J. SukK.T. The link between gut microbiota and hepatic encephalopathy.Int. J. Mol. Sci.20222316899910.3390/ijms23168999 36012266
     [Google Scholar]
  51. PortincasaP. BonfrateL. VaccaM. De AngelisM. FarellaI. LanzaE. KhalilM. WangD.Q.H. SperandioM. Di CiaulaA. Gut microbiota and short chain fatty acids: implications in glucose homeostasis.Int. J. Mol. Sci.2022233110510.3390/ijms23031105 35163038
     [Google Scholar]
  52. PeriyalwarP. DasarathyS. Malnutrition in cirrhosis: Contribution and consequences of sarcopenia on metabolic and clinical responses.Clin. Liver Dis.20121619513110.1016/j.cld.2011.12.009 22321468
     [Google Scholar]
  53. ZhuR. LiuL. ZhangG. DongJ. RenZ. LiZ. The pathogenesis of gut microbiota in hepatic encephalopathy by the gut–liver–brain axis.Biosci. Rep.2023436BSR2022252410.1042/BSR20222524 37279097
     [Google Scholar]
  54. KalaitzakisE. BjörnssonE. Hepatic encephalopathy in patients with liver cirrhosis: Is there a role of malnutrition?World J. Gastroenterol.200814213438343910.3748/wjg.14.3438 18528945
     [Google Scholar]
  55. KalaitzakisE. OlssonR. HenfridssonP. HugossonI. BengtssonM. JalanR. BjörnssonE. Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis.Liver Int.20072791194120110.1111/j.1478‑3231.2007.01562.x 17919230
     [Google Scholar]
  56. SilkD.B. Malnutrition in liver disease and its relationship to hepatic encephalopathy.Acta Chir. Scand. Suppl.1981507106111 6797170
     [Google Scholar]
  57. CampionD. GiovoI. PonzoP. SaraccoG.M. BalzolaF. AlessandriaC. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.World J. Hepatol.201911648951210.4254/wjh.v11.i6.489 31293718
     [Google Scholar]
  58. ShuklaS. ShuklaA. MehboobS. GuhaS. Meta-analysis: The effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy.Aliment. Pharmacol. Ther.201133666267110.1111/j.1365‑2036.2010.04574.x 21251030
     [Google Scholar]
  59. DazıroğluM.E.C. YıldıranH. Intestinal dysbiosis and probiotic use: Its place in hepatic encephalopathy in cirrhosis.Ann. Gastroenterol.2023362141148 36864944
     [Google Scholar]
  60. YossefS. ClarkF. BubeckS.S. AbernethyJ. BayneT. KrishnanK. YoungA. An oral formulation of the probiotic, Bacillus subtilis HU58, was safe and well tolerated in a pilot study of patients with hepatic encephalopathy.Evid. Based Complement. Alternat. Med.202020201710.1155/2020/1463108 32714397
     [Google Scholar]
  61. GonzalesA.D. ReinertJ.P. Zinc and probiotic therapy for management of hepatic encephalopathy.Sr. Care Pharm.202035417117510.4140/TCP.n.2020.171 32192566
     [Google Scholar]
  62. CaoQ. YuC.B. YangS.G. CaoH.C. ChenP. DengM. LiL.J. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis.Hepatobiliary Pancreat. Dis. Int.201817191610.1016/j.hbpd.2018.01.005 29428113
     [Google Scholar]
  63. SharmaB.C. SinghJ. Probiotics in management of hepatic encephalopathy.Metab. Brain Dis.20163161295130110.1007/s11011‑016‑9826‑x 27121846
     [Google Scholar]
  64. Pratap MouliV. BenjaminJ. SinghB.M. ManiK. GargS.K. SarayaA. JoshiY.K. Effect of probiotic VSL #3 in the treatment of minimal hepatic encephalopathy: A non‐inferiority randomized controlled trial.Hepatol. Res.201545888088910.1111/hepr.12429 25266207
     [Google Scholar]
  65. ShavakhiA. HashemiH. TabeshE. DerakhshanZ. FarzamniaS. MeshkinfarS. ShavakhiS. MinakariM. GholamrezaeiA. Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy.J. Res. Med. Sci.2014198703708 25422653
     [Google Scholar]
  66. GuptaS. VercoeA.E. PetrofE.O. Fecal microbiota transplantation: In perspective.Therap. Adv. Gastroenterol.20169222923910.1177/1756283X15607414 26929784
     [Google Scholar]
  67. BajajJ.S. The role of microbiota in hepatic encephalopathy.Gut Microbes20145339740310.4161/gmic.28684 24690956
     [Google Scholar]
  68. NielsenA.B. GluudL.L. GluudC. Non-absorbable disaccharides for hepatic encephalopathy: Systematic review of randomised trials.BMJ20043287447104610.1136/bmj.38048.506134.EE 15054035
     [Google Scholar]
  69. WuD. WuS.M. LuJ. ZhouY.Q. XuL. GuoC.Y. rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: A meta-analysis.Gastroenterol. Res. Pract.201320131910.1155/2013/236963 23653636
     [Google Scholar]
  70. ManginiC. MontagneseS. new therapies of liver diseases: hepatic encephalopathy.J. Clin. Med.20211018405010.3390/jcm10184050 34575157
     [Google Scholar]
  71. WangQ. ChenC. ZuoS. CaoK. LiH. Integrative analysis of the gut microbiota and faecal and serum short-chain fatty acids and tryptophan metabolites in patients with cirrhosis and hepatic encephalopathy.J. Transl. Med.202321139510.1186/s12967‑023‑04262‑9 37330571
     [Google Scholar]
  72. CryanJ.F. O’RiordanK.J. CowanC.S.M. SandhuK.V. BastiaanssenT.F.S. BoehmeM. CodagnoneM.G. CussottoS. FullingC. GolubevaA.V. GuzzettaK.E. JaggarM. SmithL.C.M. LyteJ.M. MartinJ.A. PerezM.A. MoloneyG. MorelliE. MorillasE. O’ConnorR. PereiraC.J.S. PetersonV.L. ReaK. RitzN.L. SherwinE. SpichakS. TeichmanE.M. van de WouwM. SilvaV.A.P. FitzsimonsW.S.E. HylandN. ClarkeG. DinanT.G. The microbiota-gut-brain axis.Physiol. Rev.20199941877201310.1152/physrev.00018.2018 31460832
     [Google Scholar]
/content/journals/ijghd/10.2174/0126662906301568240427100342
Loading

  • Article Type:     Review Article
Keyword(s): brain homestasis; Gut-brain axis; hepatic encephalopathy; neuroinflammation; neurotransmitter signaling; probiotics

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test